Taysha Gene Therapies, an early stage biotech developing AAV-based gene therapies for CNS disorders, filed on Wednesday with the SEC to raise up to $100 million in an initial public offering. Founded ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback